Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 135.9M shares rose 7.0% year over year, in line with the +7.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at +32.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.0% toward the trailing-twelve-month pace of +7.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
135.9M+5.1% QoQ
Last fiscal yearDec 2025
127.23M+5.2% YoY
LTMJun 2026
133.45M+7.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.0%——
1 year+5.2%——
3-year CAGR+32.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
127.23M USD
Year-over-year change
+5.2%
4-year CAGR
+26.7%

Weighted Avg Shares (Diluted) vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 weighted avg shares (diluted) of 133.45M shares is the highest of the 6 companies compared; the peer median is 31.7M shares.
  • Its year-over-year change of +7.1% is the 2nd highest of 4, against a peer median of +1.0%.
  • Over three fiscal years its annual growth of +32.2% compares with a peer median of +0.9%.
ARQT Competitors Peer median
Weighted Avg Shares (Diluted) for ARQT and competitors
Company Period LTM YoY 3-year CAGR
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026133.45M +7.1%+32.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
EVMNEvommune, Inc.LTM Mar 202631.7M ——
TTRXTurn Therapeutics Inc.LTM Mar 202625.17M ——
SLGLSol-Gel Technologies Ltd.LTM Mar 20262.8M -90.0%-50.6%
Peer median (excluding ARQT) 31.7M+1.0%+0.9%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.69M59.61M196.54M376.07M
Cost of Revenue763K754K4.99M19.13M36.7M
Gross Profit(763K)2.93M54.62M177.41M339.38M
Gross Margin—79.5%91.6%90.3%90.2%
Research & Development145.56M182.44M110.58M76.42M77.05M
Selling, General & Admin60.97M122.12M185.15M229.39M274.55M
Operating Expenses205.77M304.56M295.72M305.81M351.6M
Depreciation & Amortization454K934K750K2.6M4.67M
EBITDA(205.9M)(294.87M)(228.57M)(109.63M)1.78M
EBITDA Margin—-7999.8%-383.5%-55.8%0.5%
Operating Income(206.53M)(301.63M)(241.1M)(128.4M)(12.23M)
Operating Margin—-8183.0%-404.5%-65.3%-3.3%
Interest Income173K0000
Interest Expense015.65M29.71M27.17M12.08M
Other Income / Expenses173K(9.83M)(17.93M)(11M)(2.74M)
Income Before Tax(206.36M)(311.46M)(259.03M)(139.39M)(14.97M)
Pre-Tax Margin—-8449.8%-434.6%-70.9%-4.0%
Income Tax Expense003.11M647K1.17M
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Net Margin—-8449.8%-439.8%-71.3%-4.3%
EPS (Basic)(4.17)(5.66)(3.78)(1.16)(0.13)
EPS (Diluted)(4.17)(5.66)(3.78)(1.16)(0.13)
Weighted Avg Shares49.41M55.03M69.31M120.96M127.23M
Weighted Avg Shares (Diluted)49.41M55.03M69.31M120.96M127.23M

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.